Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALKYRIE Extension: Rivaroxaban vs VKA in Hemodialysis Patients with AF
NCT03799822Phase 4Completed
- Sponsor
- OLV Hospital
- Start
- May 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by OLV Hospital. Primary endpoint: Composite of fatal and non-fatal stroke and other cardiovascular events at 3 years. Started May 2017; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03799822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799822.